u/nordic_pricing

Which Boots location?

Yeah, EU rules is usually national rules.

Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.

Titration speed is a side-effect dial far more than an efficacy dial.

This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.

Crossposting this to c/semaglutide because the people who need it are not reading this community.

Yeah, dual agonism does produce a different appetite profile than GLP-1 alone.

stalled on sema, tried tirz, and the curves were actually different shapes

Sceptical. If this were true we would see it reflected in the data and we do not.

Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.

This is correct. Triple agonism is genuinely different.

research use only, handling and analysis, not protocols

Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.

This matches the trial data. SURMOUNT-1 was 97.9% body weight at 21 weeks.

I love that this community will spend 40 comments on a detail. That pedantry is why the numbers here matter.

This is correct. Private and NHS pathways are different.

positive and negative reports both need the same evidence standard

absolute risk reduction, not relative risk reduction, that is how you decide

That is net peptide content, not purity. Different number, different meaning.

tag your country in the title, bare EU gets a template